Abstract 306P
Background
Optimal adjuvant treatment for stage IA uterine papillary serous (UPSC) or clear cell carcinomas (UCCC) remains unknown. Options include no adjuvant treatment or systemic chemotherapy, Pelvic RT and Vaginal brachytherapy alone or in combination. These subtypes represent an infrequent set of patients, and hence there is lack of randomized trial data to guide optimal management. The aim of this study was to evaluate treatment patterns and relapse characteristics in this uncommon subtype based on the retrospective data from a single centre.
Methods
Clinicopathologic data, treatment patterns and relapse characteristics were retrospectively collected on patients of UPSC and UCCC treated between January 2014 and December 2018. Adjuvant treatment modalities used and their impact on relapse rates was analysed.
Results
We identified 21 patients who had undergone hysterectomy with bilateral salpingo-oophorectomy and were found to have stage 1A papillary serous or clear cell endometrial carcinoma. Nearly all patients (n-18, 85%) also underwent extended lymph node dissection of pelvic and para-aortic lymph nodes.
Median age at diagnosis was 61 years. Eighteen patients had uterine papillary serous carcinoma and three patients had clear cell histology. Eleven patients (52%) received systemic chemotherapy (six cycles of Paclitaxel and Carboplatin) with RT. and two patients received EBRT with or without VBT. Eight patients had no adjuvant treatment. At a median follow-up thirty months (range 6-63 months), six patient had experienced recurrences (28%). Nearly all the recurrences (n = 4) were in patients who received no adjuvant therapy with a relapse rate of 50% (4/8) in this subset. Four recurrences were distant metastasis while two were loco regional. At the time of last follow up, three patients with relapse had succumbed to their disease.
Conclusions
UPSC and UCCC are a distinct subtype of endometrial cancer and associated with an aggressive phenotype and high relapse rate even in patients with early stage. Systemic chemotherapy and Pelvic RT alone or in combination should always be considered in this group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract